These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8481467)

  • 1. Interference with the cytolytic activity of interleukin-2-treated lymphocytes by bovine uterine luminal protein.
    Segerson EC; Gunsett FC
    Biol Reprod; 1993 May; 48(5):1036-41. PubMed ID: 8481467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of bovine uterine luminal protein with interleukin-2 and the interleukin-2 receptor of T lymphocytes.
    Segerson EC; Libby DW
    Biol Reprod; 1990 Oct; 43(4):619-28. PubMed ID: 2289014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Substance P increases in vitro lymphokine-activated-killer (LAK) cell cytotoxicity against fresh colorectal cancer cells.
    Flageole H; Senterman M; Trudel JL
    J Surg Res; 1992 Nov; 53(5):445-9. PubMed ID: 1279274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
    Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
    No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
    Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
    J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
    Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
    Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers.
    Nio Y; Zighelboim J; Berek JS; Bonavida B
    Nat Immun Cell Growth Regul; 1990; 9(4):283-96. PubMed ID: 2215516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 modulates the expression of lymphocyte function-associated antigen-one (LFA-1) and p150,95 during the generation of lymphokine-activated killer (LAK) cells.
    Grant AJ; Merchant RE; Hall RE
    Immunology; 1989 Jan; 66(1):117-24. PubMed ID: 15493273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin 7 enhances cytolytic T lymphocyte generation and induces lymphokine-activated killer cells from human peripheral blood.
    Alderson MR; Sassenfeld HM; Widmer MB
    J Exp Med; 1990 Aug; 172(2):577-87. PubMed ID: 2142722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity against autologous, allogeneic, and xenogeneic tumor targets by human recombinant interleukin-2-activated lymphocytes from healthy dogs and dogs with lung tumors.
    Mitchell DH; Withrow SJ; Johnston MR; Kruse CA
    Am J Vet Res; 1991 Jul; 52(7):1132-6. PubMed ID: 1892269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of B16 melanoma sublines to lymphokine-activated killer cells as determined by 51Cr-release and clonogenic assays.
    Tzeng JJ; Barth RF
    J Immunol Methods; 1990 Apr; 128(2):257-66. PubMed ID: 2324514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A porcine intrauterine 4-mda component with transforming growth factor-beta activity suppresses natural killer cell responses.
    Segerson EC; Beetham PK
    J Anim Sci; 2000 Jul; 78(7):1900-6. PubMed ID: 10907833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ; Krosnick JA; Rosenberg SA
    J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
    Subauste CS; Dawson L; Remington JS
    J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity inhibition of cytolytic lymphocytes by omeprazole.
    Scaringi L; Cornacchione P; Fettucciari K; Rosati E; Rossi R; Marconi P; Capodicasa E
    Scand J Immunol; 1996 Sep; 44(3):204-14. PubMed ID: 8795713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
    Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE
    Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.